IN2012DN03297A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03297A
IN2012DN03297A IN3297DEN2012A IN2012DN03297A IN 2012DN03297 A IN2012DN03297 A IN 2012DN03297A IN 3297DEN2012 A IN3297DEN2012 A IN 3297DEN2012A IN 2012DN03297 A IN2012DN03297 A IN 2012DN03297A
Authority
IN
India
Prior art keywords
disorders
solvates
treatment
salts
pharmaceutical compositions
Prior art date
Application number
Inventor
R Hoveyda Hamid
Vezina Martin
Fournier Eric
Gagnon Rene
Bherer Patrick
Original Assignee
Tranzyme Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tranzyme Pharma Inc filed Critical Tranzyme Pharma Inc
Publication of IN2012DN03297A publication Critical patent/IN2012DN03297A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D269/00—Heterocyclic compounds containing rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms according to more than one of groups C07D261/00 - C07D267/00

Abstract

The present invention provides novel salts and solvates of cyclic compounds that bind in niicl/or are functional agonists of ihc ghrclin (growth hor-mone secrelagogiic) receptor. The invention also relates In polymorphs of these salts and solvates, phanitaeeiitical compositions continuing these salts or solvates, and meth¬ods ol' using the pharmaceutical compositions. These pharmaceutical compositions are useful as therapeutics lor a range of disease indications, in particular, for treatment and prevention of gastrointestinal disorders including, hut not limited to, postoperative ileus, gastroparesis, includ¬ing diahetic and postsurgical gastroparesis, opioid bowel dysfunction, chronic intestinal pseudo-obstruction, short bowel syndrome, functional gastrointestinal disorders and gastrointestinal dysmolilily, such as that occurring in con-junction willi other disease states, in critical care situa-tions or as a result of treatment with pharmaceutical agents. Additionally, the pharmaceutical compositions have application to the treatment and prevention of metabolic and/or endocrine disorders, cardiovascular dis-orders, central nervous system disorders, bone disorders, inflammatory disorders, hyperproliferative disorders, dis-orders characterized by apoptosis and genetic disorders.
IN3297DEN2012 2009-09-30 2010-09-29 IN2012DN03297A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24736209P 2009-09-30 2009-09-30
PCT/US2010/050661 WO2011041369A1 (en) 2009-09-30 2010-09-29 Salts, solvates, and pharmaceutical compositions of macrocyclic ghrelin receptor agonists and methods of using the same

Publications (1)

Publication Number Publication Date
IN2012DN03297A true IN2012DN03297A (en) 2015-10-23

Family

ID=43826618

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3297DEN2012 IN2012DN03297A (en) 2009-09-30 2010-09-29

Country Status (14)

Country Link
US (1) US20110245159A1 (en)
EP (1) EP2482813A4 (en)
JP (1) JP2013506676A (en)
KR (1) KR20120081166A (en)
CN (1) CN102781441A (en)
AU (1) AU2010300689A1 (en)
BR (1) BR112012007183A2 (en)
CA (1) CA2775925A1 (en)
EA (1) EA201270497A1 (en)
IL (1) IL218938A0 (en)
IN (1) IN2012DN03297A (en)
MX (1) MX2012003912A (en)
WO (1) WO2011041369A1 (en)
ZA (1) ZA201202307B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8921521B2 (en) 2003-06-18 2014-12-30 Ocera Therapeutics, Inc. Macrocyclic modulators of the Ghrelin receptor
EP1633774B1 (en) 2003-06-18 2010-02-17 Tranzyme Pharma Inc. Macrocyclic antagonists of the motilin receptor
US7491695B2 (en) * 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
US7476653B2 (en) * 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
US20090198050A1 (en) * 2003-06-18 2009-08-06 Tranzyme Pharma Inc. Macrocyclic Modulators of the Ghrelin Receptor
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
CA2807685C (en) 2010-08-13 2020-10-06 Aileron Therapeutics, Inc. P53 derived peptidomimetic macrocycle
UY34094A (en) * 2011-05-27 2013-01-03 Novartis Ag DERIVATIVES OF PIPERIDINE 3-ESPIROCYCLIC AS AGRONISTS OF GHRELINE RECEPTORS
TWI643868B (en) 2011-10-18 2018-12-11 艾利倫治療公司 Peptidomimetic macrocycles
MX362492B (en) 2012-02-15 2019-01-21 Aileron Therapeutics Inc Peptidomimetic macrocycles.
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
EP2914256B1 (en) 2012-11-01 2019-07-31 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
SG10201902594QA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
EA201791038A1 (en) 2014-11-12 2017-11-30 Лирик Фармасьютикалз Инк. TREATMENT OF INPUTABILITY OF ENTERAL FOOD
AU2016235424A1 (en) 2015-03-20 2017-10-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
KR20190091325A (en) * 2016-12-07 2019-08-05 프로제너티, 인크. Gastrointestinal tract detection methods, devices and systems

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7476653B2 (en) * 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
US7491695B2 (en) * 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
KR20070009574A (en) * 2004-02-17 2007-01-18 토마스 이. 존슨 Methods, compositions, and apparatuses for forming macrocyclic compounds
EP1723159B1 (en) * 2004-02-27 2019-06-12 Melinta Therapeutics, Inc. Macrocyclic compounds and methods of making and using the same
US8088733B2 (en) * 2006-07-06 2012-01-03 Tranzyme Pharma Inc. Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders

Also Published As

Publication number Publication date
MX2012003912A (en) 2012-08-17
CN102781441A (en) 2012-11-14
AU2010300689A1 (en) 2012-04-19
CA2775925A1 (en) 2011-04-07
EP2482813A1 (en) 2012-08-08
US20110245159A1 (en) 2011-10-06
EA201270497A1 (en) 2012-10-30
JP2013506676A (en) 2013-02-28
EP2482813A4 (en) 2013-02-27
ZA201202307B (en) 2012-12-27
BR112012007183A2 (en) 2017-06-20
KR20120081166A (en) 2012-07-18
IL218938A0 (en) 2012-07-31
WO2011041369A1 (en) 2011-04-07

Similar Documents

Publication Publication Date Title
IN2012DN03297A (en)
MA29432B1 (en) GLUCAGON RECEPTOR ANTAGONISTS, THEIR PREPARATION AND THEIR THERAPEUTIC USES
ATE502939T1 (en) DISUBSTITUTED ALKYL-8-AZABICYCLOÄ3.2.1ÜOCTANE COMPOUNDS AS MU-OPIOID RECEPTOR ANTAGONISTS
MX2010002171A (en) 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists.
SI1957484T1 (en) Glucagon receptor antagonists, preparation and therapeutic uses
MY145633A (en) 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
HK1120442A1 (en) Novel opioid antagonists
WO2007106181A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2008021851A3 (en) Novel compounds as antagonists or inverse agonists for opioid receptors
UA86621C2 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2007120270A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
UA92670C2 (en) Pyrazoline compounds as mineralocorticoid receptor antagonists , pharmaceutical use thereof, composition based thereon
DK1951659T3 (en) Glucagon Receptor Antagonists, Preparation and Therapeutic Use thereof
EA201270039A1 (en) NEW GPR 119 AGONISTS
MX2010010339A (en) Substituted cyclohexyldiamines.
EP2238105A4 (en) Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
WO2009076408A3 (en) 3 -carboxypropyl-aminotetralin derivatives as mu opioid receptor antagonists
WO2009076399A3 (en) Aminotetralin compounds as mu opioid receptor antagonists
NZ593377A (en) Crystalline forms of a 3-carboxypropyl-aminotetralin compound
MX2011008857A (en) Oxyindole derivatives with motilin receptor agonistic activity.
HK1102303A1 (en) Synthesis of ccr5 receptor antagonists ccr5
IL195969A0 (en) Azaindole derivatives with a combination of partial nicotinic acetylcholine receptor agonism and dopamine reuptake inhibition
UA97374C2 (en) Azaindole derivatives with a combination of partial nicotinic acetylcholine receptor agonism and dopamine reuptake inhibition
EP2307394A4 (en) Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same